DISCOUNT OPTIONSSCHEIN - NOVO NORDISK ADR B | Real-time Boerse Frankfurt Warrants 02:05:00 13/06/2024 pm IST | ||
| 1.14 EUR | +0.88% |
|
| Current month | +18.95% | ||
| 1 month | +31.40% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 13/24/13 | 1.14 | +0.88% |
| 12/24/12 | 1.13 | +0.89% |
| 11/24/11 | 1.12 | -2.61% |
| 10/24/10 | 1.15 | +0.88% |
| 07/24/07 | 1.14 | +1.79% |
Real-time Boerse Frankfurt Warrants
Last update June 13, 2024 at 02:05 pm IST
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| WKN | VM7327 |
| ISIN | DE000VM73278 |
| Date issued | 05/01/2024 |
| Strike | 130 $ |
| Maturity | 20/06/2025 (373 Days) |
| Parity | 10 : 1 |
| Emission price | 0.39 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.15 € |
|---|---|
| Lowest since issue | 0.44 € |
| Spread | 0.01 € |
| Spread % | 0.88% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
989.6
DKK
Average target price
929.5
DKK
Spread / Average Target
-6.08%
- Stock Market
- Certificates
- Certificat
